News | October 13, 2014

FDA Advisory Committee Panel Votes In Favor Of Watchman Left Atrial Appendage Closure Device

Catheter-delivered heart implant one step closer to full FDA approval

October 13, 2014 — After reviewing updated data and analysis for the Boston Scientific Watchman left atrial appendage (LAA) closure device, the U.S. Food and Drug Administration (FDA) Circulatory System Devices Panel of the Medical Devices Advisory Committee voted in favor of the device. By a vote of 6 to 5 (with 1 abstention) the panel concluded the benefits of the Watchman device outweigh the potential risks.

Furthermore, the panel voted there was reasonable assurance the device is safe (12 yes to 0 no). On the question of reasonable assurance of effectiveness, the panel vote was unfavorable (6 yes to 7 no). The panel provided substantial input and guidance related to the proposed indications for use and target patient population. There was widespread agreement among the panel members that the device provides a much needed alternative to long-term anticoagulation for some patients. While not bound by this vote, the FDA takes Advisory Panel comments and recommendations into account when reviewing the Watchman device application. The company is committed to working with the FDA to address the panel's comments.

"There is a strong clinical need for a proven device alternative to long-term warfarin therapy for my high stroke risk patients with non-valvular atrial fibrillation," said Vivek Reddy, M.D., director of the Cardiac Arrhythmia Service at Mount Sinai Medical Center and co-principal investigator of the PROTECT AF and PREVAIL studies. "I'm encouraged that the panel recognized the importance of having the Watchman device as an option for appropriate patients."

The Watchman device is a catheter-delivered heart implant designed to close the LAA in order to prevent the migration of blood clots from the LAA, and thus reduce the incidence of stroke and systemic embolism for higher risk patients with non-valvular atrial fibrillation (AF).

The committee's positive vote followed a review of the most recent clinical data and analysis from two randomized control trials, PROTECT AF and PREVAIL, as well as from the CAP (Continued Access Protocol) and CAP2 registries. The Watchman device is the most studied LAA device and the only one with long-term clinical data from more than 2,400 patients and nearly 6,000 patient-years of follow-up in clinical studies. The Watchman device was approved for sale in Europe in 2005 and is currently approved in more than 70 countries across the globe. In the United States, the Watchman device is an investigational device, limited to investigational use and not available for sale.

For more information: www.bostonscientific.com

Related Content

Gore Cardioform ASD Occluder Receives FDA Approval
Technology | Structural Heart Occluders | June 10, 2019
W. L. Gore & Associates (Gore) announced the U.S. Food and Drug Administration’s (FDA’s) premarket approval (PMA)...
Le Bonheur Children's Hospital Implants First Abbott Amplatzer Piccolo Occluder
News | Structural Heart Occluders | February 13, 2019
Le Bonheur Children's Hospital cardiologists in Memphis, Tenn., implanted the Amplatzer Piccolo Occluder, the world's...
FDA Approves Abbott's Amplatzer Piccolo Occluder
News | Structural Heart Occluders | January 16, 2019
Abbott announced the U.S. Food and Drug Administration (FDA) approved the Amplatzer Piccolo Occluder to treat patent...
FDA Approves Gore Cardioform Septal Occluder for PFO Closure Prevent Recurrent Ischemic Stroke
Technology | Structural Heart Occluders | April 03, 2018
April 3, 2018 — Following the unprecedented Gore REDUCE Clinical Study conclusion that closure of patent foramen oval
University of Alabama at Birmingham, Amplatzer PFO Occluder, first implementation
News | Structural Heart Occluders | February 15, 2017
Doctors at the University of Alabama at Birmingham have implemented the first U.S. Food and Drug Administration (FDA)-...
Overlay Init